Sign in Subscribe
Class action lawsuits

Altimmune, Inc. Faces Securities Lawsuit Alleging Inflated Expectations and Failure to Achieve Statistical Significance

Strategic Insights

— 1 min read

A class action securities lawsuit has been filed against Altimmune, Inc. (NASDAQ: ALT), alleging securities fraud between August 10, 2023, and June 25, 2025. The lawsuit claims that the company inflated expectations ahead of the topline results from the IMPACT Phase 2b MASH trial of Pemvidutide, only to announce a failure to achieve statistical significance in fibrosis reduction. This announcement led to a dramatic decline in the company's stock price, with a 53.2% drop from $7.71 to $3.61 per share in a single day.

Key Takeaways:

  • The lawsuit accuses Altimmune of providing inflated expectations ahead of the topline results from the IMPACT Phase 2b MASH trial of Pemvidutide.
  • The company allegedly attributed the failure to achieve statistical significance to the Phase 2 nature of the trial, stating that they were hoping for better results following the Phase 3 trial.
  • The price of Altimmune's common stock declined dramatically by 53.2% from $7.71 to $3.61 per share in a single day on June 26, 2025.
  • The lawsuit seeks to recover losses of shareholders who were adversely affected by the alleged securities fraud.
  • Levi & Korsinsky LLP, a nationally-recognized securities litigation firm, is representing the plaintiffs in the case.
  • The firm has secured hundreds of millions of dollars for aggrieved shareholders and has extensive expertise representing investors in complex securities litigation.

Statistics:

  • Decline in Altimmune's stock price: 53.2% from $7.71 to $3.61 per share on June 26, 2025.
  • Date of topline results announcement: June 26, 2025.
  • Time period of alleged securities fraud: August 10, 2023, to June 25, 2025.

Sources:

  • Levi & Korsinsky LLP, "Altimmune, Inc. Lawsuit Submission Form 2" - https://zlk.com/pslra-1/altimmune-inc-lawsuit-submission-form-2?prid=161534&wire=5&utm_campaign=11
  • Newsfile Corp., "Altimmune, Inc. Investor Suit" - https://www.newsfilecorp.com/release/262577

Read more